Global Reritinib Mesylate Tablets Market Strategic Research Report

Scope of the Report

The global Reritinib Mesylate Tablets market size is predicted to grow from US$ 34.24 million in 2025 to US$ 118 million in 2032; it is expected to grow at a CAGR of 7.2% from 2026 to 2032.

Reritinib Mesylate Tablets are a highly selective oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with reritinib mesylate as the main ingredient. This drug can irreversibly inhibit EGFR sensitive mutations and T790M resistance mutations, block downstream signaling pathway transmission, inhibit tumor cell proliferation, invasion and metastasis, and exert antitumor effects. Clinically, it is mainly used for locally advanced or metastatic non-small cell lung cancer with EGFR T790M mutation-positive after progression on EGFR tyrosine kinase inhibitor therapy. Characterized by high targeting, convenient oral administration, controllable drug resistance and favorable safety profile, it is an important second-line targeted therapeutic drug for advanced non-small cell lung cancer.In 2025, global Reritinib Mesylate Tablet production reached approximately 120,000 units.

As a domestic third-generation EGFR-TKI, Reritinib Mesylate Tablets are an important innovative product in China's lung cancer targeted therapy market. Relying on its unique molecular structure and excellent clinical efficacy, it has a differentiated advantage in the domestic competitive landscape of third-generation EGFR-TKIs. The drug is approved for non-small cell lung cancer positive for EGFR-sensitive mutations and T790M resistance mutations, with outstanding clinical efficacy and safety. It has also been included in the national medical insurance catalogue, significantly improving patients’ medication accessibility. With the implementation of medical insurance coverage for first-line indications and the upgrading of clinical guideline recommendations, its market penetration continues to rise, forming unique competitiveness among similar domestic drugs. In the future, with the advancement of combination therapy research, indication expansion, and optimization of medical insurance policies, Reritinib Mesylate Tablets will further consolidate its market position, promote a higher level of import substitution of domestic EGFR-targeted drugs, and support the high-quality development of China's precision lung cancer therapy market.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Reritinib Mesylate Tablets market?

What factors are driving Reritinib Mesylate Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Reritinib Mesylate Tablets market opportunities vary by end market size?

How does Reritinib Mesylate Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Reritinib Mesylate Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 100mg / tablet
• 80mg / tablet

Segment by Packaging

• Bottle
• Box

Segment by Sales Channel

• Hospital
• Retail
• Online

Segment by Production Technology

• Innovator
• Generic

Segment by Application

• EGFR-Sensitive Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Non-Small Cell Lung Cancer With T790M Resistance Mutation After Progression on EGFR-TKI Therapy
• Second-Line Targeted Therapy for Advanced Non-Small Cell Lung Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Reritinib Mesylate Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in EGFR-Sensitive Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer With T790M Resistance Mutation After Progression on EGFR-TKI Therapy, Second-Line Targeted Therapy for Advanced Non-Small Cell Lung Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact